Postherpetic neuralgia (PHN) is a condition associated with debilitating neuropathic pain that arises as a complication of herpes zoster infection (shingles). According to the Centers for Disease Control and Prevention (CDC), the condition is uncommon among people younger than 40, but it can occur in up to one-third of untreated individuals 60 and older. People are more likely to develop PHN as they age.1
The pain from PHN may be more severe and debilitating among elderly patients. In addition, treating this neuropathic pain condition can be complicated in elderly patients because of polypharmacy, drug dosing schedules, adverse events, drug-drug interactions, and patient comorbidities.
Compliance is also an issue with elderly patients due to forgetfulness and issues associated with drug sensitivity. “Patients often have difficulty taking the medication as directed, which is usually three times a day. As a result, these patients are often unable to obtain full therapeutic benefit of the medication,” said Anita Gupta, DO, PharmD, of Drexel University College of Medicine and Hahnemann University Hospital in Philadelphia, PA. Finding options that improve compliance and reduce adverse events would likely improve pain control and outcomes in elderly patients.
Once-Daily Gastroretentive Gabapentin Improves Compliance and Outcomes in Elderly
In a 2013 study published in “Drugs & Aging,” Gupta and a colleague evaluated whether once-daily gastroretentive gabapentin to treat PHN worked as well in elderly patients as in patients younger than 75. Results showed that once-daily gastroretentive gabapentin was well tolerated in both groups and provided significant pain relief. Overall adherence was high.3 “Our study found that elderly patients did much better with the once-daily dosing simply because it was easier to take regularly. Our study participants were compliant with taking the once-daily dose of gastroretentive gabapentin, which also resulted in minimizing side effects, better pain control, improved patient satisfaction, and better sleep,” Gupta said.
In order to determine whether the efficacy and tolerability of once-daily gastroretentivegabapentin was similar between older and younger patients, the researchers used datafrom two, Phase 3 placebo-controlled trials and analyzed the data by age subgroups (527patients <75 years of age; 192 patients ≥75 years age). Within 2 weeks, the majority ofpatients were titrated to the effective dose of 1800mg once daily; absolute change andpercent change in average daily pain (ADP) score from baseline to week 10 was usedfor efficacy assessment. At week 10, compared to placebo, the percent change frombaseline in ADP was significantly greater in patients taking the once-daily gastroretentivegabapentin; this effect was seen in both age subgroups. The mean difference in ADPwas similar between both age groups (difference between once-daily gastroretentivegabapentin and placebo: <75yrs: -8.4%; ≥75yrs: -12.3%). Based on this data, the authorsconcluded that treatment with once-daily gastroretentive gabapentin was as effective intreating PHN pain in elderly patients as it was in younger patients.
In another study published in The Clinical Journal of Pain, Edwin Dunteman, MD, of the A & A Pain Institute of Saint Louis and the Missouri Baptist Medical Center evaluated the safety and efficacy of once-daily gastroretentive gabapentin as an option for treating PHN pain in elderly patients.2
The researchers found that once-daily gabapentin was effective and well tolerated in the elderly. “We found that both the elderly and those 70 and younger had similar improvement in the worse, least, and average pain they experienced from PHN. Both age groups experienced significant increases in general activity, mood, walking ability, sleep, enjoyment of life, work, and relationships. Those 70 or [younger] tended to have slightly better responses,” said Dunteman.
For clinical trials with once-daily gastroretentive gabapentin, the results, according to Dunteman, have suggested a considerably lower incidence of side effects than immediate-release gabapentin. His study found overall dizziness and somnolence with once-daily gabapentin was 10.9% and 4.5%, respectively, compared to 28% and 24% with immediate-release gabapentin, respectively. “There were fewer side effects with longer-acting gabapentin, in part, due to its sustained release over the entire day, versus the peaks and valleys associated with dosing three times per day,” said Dunteman.
Overall, it appears to be much easier for patients to take gabapentin once a day, especially elderly patients. “There was a higher rate of compliance, fewer side effects, and improved efficacy with the longer-acting dose. It is always nicer to take [medication] once per day, as the elderly have a tendency to forget,” said Dunteman.
According to Gupta, the once-daily gastrorententive gabapentin makes an improved difference overall in clinical practice for elderly individuals with PHN and other neuropathic pain conditions in which patients are unable to handle multiple doses in a single day.
- CDC. Shingles (Herpes Zoster). Available at: http://www.cdc.gov/shingles/about/complications.html. Accessed: September 19, 2014.
- Markley HG, Dunteman ED, et al. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). Clin J Pain. [Published online ahead of print September 17, 2014].
- Gupta A, Li S. Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. Drugs & Aging. 2013;30 (12):999-1008.
This article originally appeared on MPR